Basaglar is a long-acting insulin that may be available through Medicare Part D. If a person’s drug plan includes Basaglar, the plan cannot charge more than $35 per month. Basaglar is a brand ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...

Yes, weightloss drugs can help you lose weight – but they can also boost your health in unexpected ways. Good Housekeeping’s ...

Xultophy is a combination of insulin and liraglutide and is used for treatment ... It was later marketed in a long-acting form under the brand name Bydureon BCise. Byetta was registered for use in ...

Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology ... system for people who discontinue long-acting GLP-1 formulations ...

to upgrade its production of long-acting insulin shots in Germany, a person familiar with the plan told Reuters on Monday. French drugmaker Sanofi is nearing a decision to invest between 1.3 ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic, Wegovy, ...

The data collectors were trained and were familiarized with insulin categorizations, such as short- versus long-acting and originator brands (OBs) versus biosimilar (BS), before field survey. The data ...